Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2018

View Archived Issues

Novartis offers overview of first quarter 2018

Galapagos initiates clinical trial with triple combination therapy in cystic fibrosis

Afecta Pharmaceuticals patents novel hgh mobility group protein B1 inhibitors

U.S. Navy describes novel anti-CD20 antibodies

Procalcitonin predicts malignant cerebral edema after massive cerebral infarction

Initiation of phase Ib trial of CMP-001 plus atezolizumab in anti-PD-1/PD-L1 resistant NSCLC

Nektar, Takeda to evaluate NKTR-214 in combination with TAK-659

Completion of phase I study of tozuleristide in pediatric brain tumor surgery

Third Rock Ventures launches Cedilla Therapeutics

Results on sodium oxybate presented in pediatric patients with narcolepsy type 1

First patient enrolled in phase III trial of topical ocular reproxalap

Boehringer Ingelheim and Topas Therapeutics enter research agreement

Curadev Pharma targets ACSS2 for antitumor agents

Takeda set to begin voluntary and conditional public takeover bid for TiGenix

FDA approves Jynarque to slow kidney function decline in adults with ADPKD

Researchers present novel IDO-1 inhibitor for cancer

Shire willing to recommend Takeda's revised proposal to shareholders

FDA grants RMAT designation to ABO-102 for MPS IIIA

Novel farnesoid X receptor agonists described by Enanta Pharmaceuticals

Bristol-Myers Squibb presents new TYK2 inhibitors

New 5'-nucleotidase inhibitors identified at Arcus Biosciences

FDA gives orphan drug designation to AMP-L2.7.D7 for congenital erythropoietic porphyria

Theratechnologies to seek European approval for Trogarzo based on available data

Synthetic Biologics withdraws breakthrough therapy designation for ribaxamase

FDA grants fast track designation to EC-18 for chemoradiation-induced oral mucositis

Novel CDK4/6 inhibitor TQB-3616 presented for cancer therapy

FDA approves expanded indication for Trelegy Ellipta in COPD

Alkahest initiates phase II study of GRF-6019 in Alzheimer's disease

Orexigen announces asset purchase agreement for sale of company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.